[.
]
Action/Kinetics:
By inhibiting prostaglandin synthesis, flurbiprofen reverses prostaglandin-induced vasodilation, leukocytosis, increased vascular permeability, and increased intraocular pressure. Also inhibits miosis occurring during cataract surgery.
PO form, time to peak levels: 1.5 hr;
t
1/2: 5.7 hr.
Uses:
Ophthalmic: Prevention of intraoperative miosis.
PO: Rheumatoid arthritis, osteoarthritis.
Investigational: Inflammation following cataract surgery, uveitis syndromes. Topically to treat cystoid macular edema. Primary dysmenorrhea, sunburn, mild to moderate pain.
Contraindications:
Dendritic keratitis.
Special Concerns:
Use with caution in clients hypersensitive to aspirin or other NSAIDs and during lactation. Wound healing may be delayed with use of the ophthalmic product. Acetylcholine chloride and carbachol may be ineffective when used with ophthalmic flubiprofen. Safety and efficacy in children have not been established.
Additional Side Effects:
Ophthalmic: Ocular irritation, transient stinging or burning following use, delay in wound healing. Increased bleeding of ocular tissues in conjunction with ocular surgery.
How Supplied:
Flurbiprofen:
Tablet: 50 mg, 100 mg
Flurbiprofen sodium:
Ophthalmic solution: 0.03%
Dosage
?Ophthalmic Drops
Beginning 2 hr before surgery, instill 1 gtt q 30 min (i.e., total of 4 gtt of 0.03% solution).
?Tablets
Rheumatoid arthritis, osteoarthritis.
Adults, initial: 200-300 mg/day in divided doses b.i.d.-q.i.d.;
then, adjust dose to client response. Doses greater than 300 mg/day are not recommended.
Dysmenorrhea.
50 mg q.i.d.
